Literatura académica sobre el tema "Drug repurposing against COVID-19"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Drug repurposing against COVID-19".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Drug repurposing against COVID-19"
Mohate, Pratiksha y Madhav D. Zade. "REVIEW ON DRUG REPURPOSING DRUG USEFUL AGAINST COVID-19". International Journal of Engineering Applied Sciences and Technology 5, n.º 2 (30 de junio de 2020): 449–55. http://dx.doi.org/10.33564/ijeast.2020.v05i02.074.
Texto completoRodrigues, Liliana, Renata Bento Cunha, Tatiana Vassilevskaia, Miguel Viveiros y Celso Cunha. "Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates". Molecules 27, n.º 9 (23 de abril de 2022): 2723. http://dx.doi.org/10.3390/molecules27092723.
Texto completoKhataniar, Ankita, Upasana Pathak, Sanchaita Rajkhowa y Anupam Nath Jha. "A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19". COVID 2, n.º 2 (26 de enero de 2022): 148–67. http://dx.doi.org/10.3390/covid2020011.
Texto completoPuccetti, Matteo, Claudio Costantini, Maurizio Ricci y Stefano Giovagnoli. "Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics". Pharmaceutics 13, n.º 4 (5 de abril de 2021): 494. http://dx.doi.org/10.3390/pharmaceutics13040494.
Texto completoWahedi, Hussain Mustatab y Deeba Amraiz. "Repurposing of Antiviral Drugs for Covid-19 Therapy". Life and Science 1, supplement (23 de diciembre de 2020): 10. http://dx.doi.org/10.37185/lns.1.1.151.
Texto completoKumari, Priyanka, Bikram Pradhan, Maria Koromina, George P. Patrinos y Kristel Van Steen. "Discovery of new drug indications for COVID-19: A drug repurposing approach". PLOS ONE 17, n.º 5 (24 de mayo de 2022): e0267095. http://dx.doi.org/10.1371/journal.pone.0267095.
Texto completoKumari, Kanchan y Sandip K Mishra. "Artemisinin and its Derivatives as Repurposing Drug against COVID-19". Acta Scientific Cancer Biology 4, n.º 7 (22 de junio de 2020): 21–23. http://dx.doi.org/10.31080/ascb.2020.04.0237.
Texto completoParvathaneni, Vineela y Vivek Gupta. "Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges". Life Sciences 259 (octubre de 2020): 118275. http://dx.doi.org/10.1016/j.lfs.2020.118275.
Texto completoCiliberto, Gennaro y Luca Cardone. "Boosting the arsenal against COVID-19 through computational drug repurposing". Drug Discovery Today 25, n.º 6 (junio de 2020): 946–48. http://dx.doi.org/10.1016/j.drudis.2020.04.005.
Texto completoKolitz, Sarah, Jason Kim, Jenny Zhang, Yoonjeong Cha, Sailaja Battula, Rebecca Kusko, Rajaraman Krishnan, Benjamin Zeskind y Howard Kaufman. "477 Deep learning to drive COVID-19 rapid drug repurposing". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (noviembre de 2020): A509. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0477.
Texto completoTesis sobre el tema "Drug repurposing against COVID-19"
Brás, Ana Luzia Alves. "Relatórios de Estágio e Monografia intitulada “Drug Repurposing: Uma oportunidade para as empresas farmacêuticas nacionais”". Master's thesis, 2020. http://hdl.handle.net/10316/93040.
Texto completoPor drug repurposing (DR) entende-se o recurso a fármacos já aprovados para determinada patologia, com o intuito de identificar novas propriedades, direcionando-os para uma nova indicação terapêutica. Pela existência de dados de segurança, esta abordagem beneficia de custos mais reduzidos e de intervalos de tempo mais curtos. Desta forma, combinam-se medicamentos para criar um tratamento com eficácia superior, comparativamente, ao seu uso em monoterapia, ou investigam-se novos mecanismos de ação. Desta investigação surgem novas indicações terapêuticas, normalmente, na mesma classe farmacológica.Com o intuito de avaliar a hipótese do DR poder ser uma oportunidade para as empresas farmacêuticas nacionais, analisou-se o benefício de colaborações entre organizações, identificou-se uma área emergente e ponderou-se as suas vantagens e desvantagens, bem como os passos futuros a executar.Em 2020, a doença que é provocada pela infeção por coronavírus (COVID-19) tornou-se uma ameaça à saúde pública, a nível mundial. Por este motivo, emergiu a necessidade de uma vacina e / ou um medicamento para que a transmissão da doença estagnasse e para combater a mortalidade que lhe está associada. Nas circunstâncias atuais, o DR surge como alternativa para avançar de forma fugaz na procura por uma solução para travar esta pandemia, ao contrário do que aconteceu com outras antecedentes. Esta ferramenta tem custos reduzidos associados, pelo que pode ser considerada uma oportunidade de investimento por parte das empresas farmacêuticas nacionais.De notar que apesar da existência de inúmeros benefícios, ainda se encontram barreiras por ultrapassar, tais como ampliar as propostas de financiamento, simplificar a conjetura regulamentar e identificar métodos que minimizem erros fortuitos.
Drug repurposing (DR) means the use of drugs already approved for a given pathology, to identify new properties, directing them to a new therapeutic indication. Due to the existence of safety data, this approach benefits from lower costs and shorter time intervals. In this way, drugs are combined to create a treatment with superior efficacy, compared to its use in monotherapy, or new mechanisms of action are investigated. From this research new therapeutic indications usually arise in the same pharmacological class.In order to evaluate the hypothesis that DR may be an opportunity for national pharmaceutical companies, the benefit of collaborations between organizations was analysed, an emerging area was identified and its advantages and disadvantages were pondered, as well as the future steps to be taken.In 2020, the disease caused by coronavirus infection (COVID-19) became a threat to public health worldwide. For this reason, the need for a vaccine and/or a drug has emerged to stagnate the transmission of the disease and to combat the mortality associated with it. In the current circumstances, DR emerges as an alternative to move forward fleetingly in the search for a solution to stop this pandemic, unlike what happened with other precedents. This tool has low associated costs and can therefore be considered an investment opportunity by national pharmaceutical companies.It should be noted that despite the existence of numerous benefits, there are still obstacles to be overcome, such as extending funding proposals, simplifying the regulatory conjecture, and identifying methods to minimise fortuitous errors.
Libros sobre el tema "Drug repurposing against COVID-19"
Drago, Filippo y Rafael Maldonado, eds. Drug Repurposing for COVID-19 Therapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-485-8.
Texto completoDrago, Filippo y Rafael Maldonado, eds. Drug Repurposing for COVID-19 Therapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-485-8.
Texto completoSekeres, Mikkael A. Drugs and the FDA. The MIT Press, 2022. http://dx.doi.org/10.7551/mitpress/13620.001.0001.
Texto completoCapítulos de libros sobre el tema "Drug repurposing against COVID-19"
Yadav, Monu, Pratibha Dhakla, Rahul Rawat, Mini Dahiya y Anil Kumar. "Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19". En Drug Repurposing for Emerging Infectious Diseases and Cancer, 543–68. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_24.
Texto completoDwivedi, Shailendra, Aakanksha Rawat, Amit Ranjan, Ruchika Agrawal, Radhieka Misra, Sunil Kumar Gupta, Surekha Kishore y Sanjeev Misra. "Drug Repurposing and Novel Antiviral Drugs for COVID-19 Management". En COVID-19, 74–95. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003190394-7.
Texto completoTruong, Anh T. L., Agata Blasiak, Mathias Egermark y Dean Ho. "AI for Drug Repurposing in the Pandemic Response". En Artificial Intelligence in Covid-19, 59–84. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08506-2_3.
Texto completoAbdelhady, Aya Salama, Yaseen A. M. M. ElShaier, Mohamed S. Refaey, Ahmed Elsyaed Elmasry y Aboul Ella Hassanien. "Intelligent Drug Descriptors Analysis: Toward COVID-19 Drug Repurposing". En Studies in Computational Intelligence, 173–91. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-91103-4_10.
Texto completoTripathi, Manish Kumar, Sujata Sharma, Tej P. Singh, A. S. Ethayathulla y Punit Kaur. "Computational Intelligence in Drug Repurposing for COVID-19". En Studies in Computational Intelligence, 273–94. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-8534-0_14.
Texto completoBoutorh, Aicha, Kaouter Marref y Naamat Ellah Dehiri. "Graph Representation Learning for Covid-19 Drug Repurposing". En Advances in Computing Systems and Applications, 61–72. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-12097-8_6.
Texto completoAl-Harrasi, Ahmed, Saurabh Bhatia, Tanvir Kabir, Tapan Behl y Deepak Kaushik. "Role of Drug Repurposing and Natural Products". En Role of Essential Oils in the Management of COVID-19, 61–97. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003175933-6.
Texto completoO'Reilly, Sophie, Matthew Angeliadis, Ross Murtagh y Virginie W. Gautier. "Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic". En COVID-19, 39–68. Sheffield, United Kingdom: European Respiratory Society, 2021. http://dx.doi.org/10.1183/2312508x.10024020.
Texto completoChopra, Simran, Aditya Dahiya, Ashrit Nair, Navneet Sharma y Rakesh Kumar Sharma. "2-Deoxy-d-Glucose: A Repurposed Drug for COVID-19 Treatment". En Drug Repurposing for Emerging Infectious Diseases and Cancer, 479–500. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_20.
Texto completoVerma, Rohit, Shivani Raj, Umang Berry, C. T. Ranjith-Kumar y Milan Surjit. "Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges". En Drug Repurposing for Emerging Infectious Diseases and Cancer, 451–78. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_19.
Texto completoActas de conferencias sobre el tema "Drug repurposing against COVID-19"
Bastikar, Alpana, Virupaksha Bastikar, Santosh Chhajed y PramodKumar Gupta. "Targeting SARS-CoV2 Main Protease using HTVS and simulation analysis: A drug repurposing approach against COVID-19". En 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07803.
Texto completoAdnan, Md, Md Nazim Uddin Chy, Md Riad Chowdhury y A. T. M. Mostafa Kamal. "<em>In silico</em> virtual screening of known drugs against SARS-CoV-2 3CL protease: A drug repurposing approach for COVID-19". En 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07363.
Texto completo"Drug repurposing for COVID-19 therapy: challenges and opportunities". En Bioinformatics of Genome Regulation and Structure/Systems Biology (BGRS/SB-2022) :. Institute of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences, 2022. http://dx.doi.org/10.18699/sbb-2022-198.
Texto completoAqeel, Imra, Sadia Zafar, Muhammad Bilal y Abdul Majid. "Drug Repurposing for CoVID-19 Spike Protein through Molecular Docking". En 2022 International Conference on Recent Advances in Electrical Engineering & Computer Sciences (RAEE & CS). IEEE, 2022. http://dx.doi.org/10.1109/raeecs56511.2022.9954482.
Texto completoWang, Qingyun, Manling Li, Xuan Wang, Nikolaus Parulian, Guangxing Han, Jiawei Ma, Jingxuan Tu et al. "COVID-19 Literature Knowledge Graph Construction and Drug Repurposing Report Generation". En Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies: Demonstrations. Stroudsburg, PA, USA: Association for Computational Linguistics, 2021. http://dx.doi.org/10.18653/v1/2021.naacl-demos.8.
Texto completoPacl, H. T., J. L. Tipper, G. D. Holder, R. R. Sevalkar, S. Nadeem, K. C. Chinta, A. Crouse, A. J. C. Steyn, M. Might y K. S. Harrod. "Identification and Assessment of FDA-Approved Drugs for Repurposing as Single and Combination Therapies Against SARS-CoV-2 Infection". En American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3767.
Texto completoRabbani, Naila, Paul John Thornalley, Maryam Al-Motawa y Mingzhan Xue. "Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection". En Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.
Texto completoChowdhury, Md Riad y Sadia Akter. "<em>In silico </em>screening of therapeutic agents for COVID-19: A drug repurposing approach". En 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11359.
Texto completoSvitich, Oxana A., N. D. Abramova, I. V. Bisheva, E. A. Khromova, S. A. Skhodova, N. O. Kryukova, I. A. Baranova et al. "The level of sIgA in nasal secretions and the incidence of complications in hospitalized patients with COVID-19 against an immunotropic drug". En ERS Lung Science Conference 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/23120541.lsc-2022.258.
Texto completoCunha, Vinícius Gonçalves Portilho, Alda Maria de Sousa Mendonça, Amanda Selvátici dos Santos Dias y Ketteny de Lima Rodrigues. "Pediatric onset multiple sclerosis: defying disability – a case report". En XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.661.
Texto completo